浙江医学
浙江醫學
절강의학
ZHEJIANG MEDICAL JOURNAL
2015年
12期
1068-1069,1072
,共3页
乌司他丁%重症急性胰腺炎%肿瘤坏死因子- α%白介素- 6%白介素- 10
烏司他丁%重癥急性胰腺炎%腫瘤壞死因子- α%白介素- 6%白介素- 10
오사타정%중증급성이선염%종류배사인자- α%백개소- 6%백개소- 10
Ulinastatin%Severe acute pancreatitis%Tumor necrosis factor- α%Interleukin- 6%Interleukin- 10
目的：研究乌司他丁对重症急性胰腺炎（SAP）患者血清TNF-α、IL-6、IL-10水平的影响。方法对2010年1月至2014年1月收治的160例SAP患者，按随机数字表法分为对照组和治疗组，每组80例。观察两组患者治疗前后血清TNF-α、IL-6、IL-10水平变化及临床疗效。结果治疗前两组患者血清TNF-α、IL-6、IL-10水平比较，差异均无统计学意义（均P＞0.05）。治疗7d后两组患者血清TNF-α、IL-6水平均较治疗前显著降低（均P＜0.01），并且治疗组下降更明显（均P＜0.01）；血清IL-10水平均较治疗前显著上升（均P＜0.01），并且治疗组上升更明显（均P＜0.01）。对照组治疗总有效率73.75%，治疗组总有效率86.25%，两组比较差异有统计学意义（P＜0.05）。结论乌司他丁对SAP治疗有效，能有效调控患者机体的炎症反应，阻断炎症进程，加速患者康复。
目的：研究烏司他丁對重癥急性胰腺炎（SAP）患者血清TNF-α、IL-6、IL-10水平的影響。方法對2010年1月至2014年1月收治的160例SAP患者，按隨機數字錶法分為對照組和治療組，每組80例。觀察兩組患者治療前後血清TNF-α、IL-6、IL-10水平變化及臨床療效。結果治療前兩組患者血清TNF-α、IL-6、IL-10水平比較，差異均無統計學意義（均P＞0.05）。治療7d後兩組患者血清TNF-α、IL-6水平均較治療前顯著降低（均P＜0.01），併且治療組下降更明顯（均P＜0.01）；血清IL-10水平均較治療前顯著上升（均P＜0.01），併且治療組上升更明顯（均P＜0.01）。對照組治療總有效率73.75%，治療組總有效率86.25%，兩組比較差異有統計學意義（P＜0.05）。結論烏司他丁對SAP治療有效，能有效調控患者機體的炎癥反應，阻斷炎癥進程，加速患者康複。
목적：연구오사타정대중증급성이선염（SAP）환자혈청TNF-α、IL-6、IL-10수평적영향。방법대2010년1월지2014년1월수치적160례SAP환자，안수궤수자표법분위대조조화치료조，매조80례。관찰량조환자치료전후혈청TNF-α、IL-6、IL-10수평변화급림상료효。결과치료전량조환자혈청TNF-α、IL-6、IL-10수평비교，차이균무통계학의의（균P＞0.05）。치료7d후량조환자혈청TNF-α、IL-6수평균교치료전현저강저（균P＜0.01），병차치료조하강경명현（균P＜0.01）；혈청IL-10수평균교치료전현저상승（균P＜0.01），병차치료조상승경명현（균P＜0.01）。대조조치료총유효솔73.75%，치료조총유효솔86.25%，량조비교차이유통계학의의（P＜0.05）。결론오사타정대SAP치료유효，능유효조공환자궤체적염증반응，조단염증진정，가속환자강복。
Objective To investigate the changes of serum TNF- α, IL- 6, IL- 10 levels in patients with severe acute pancreatitis (SAP) after ulinastatin treatment. Methods A total of 160 patients, admitted from 2010 January to 2014 January, were randomly divided into the control group (n=80) and ulinastatin group (n=80). The serum levels of TNF- α, IL- 6 and IL- 10 were measured before and after treatment, and the clinical outcomes were assessed, Results There was no difference in serum levels of TNF- α, IL- 6 and IL- 10 between control group and ulinastatin group before treatment. Serum TNF- α and IL- 6 levels were significantly decreased and IL- 10 level was significantly increased in both groups after 7 days of treatment (P<0.01), while the changes in ulinastatin group was more marked than those in control group (P<0.01). The clinical curative effect of ulinastatin was higher than that of control group (86.25%vs 73.75%, P<0.05). Conclusion Ulinastatin can inhibit inflammatory reaction in SAP patients, which is associated with decrease of serum TNF- αand IL- 6 levels and increase of IL- 10 level.
